Tag: the war on (some) drugs

San Francisco buys vodka shots for homeless alcoholics in taxpayer-funded program

The City of San Francisco is providing free beer and vodka shots to homeless alcoholics at taxpayer expense under a little-known pilot program. 

The “Managed Alcohol Program” operated by San Francisco’s Department of Public Health serves regimented doses of alcohol to voluntary participants with alcohol addiction in an effort to keep the homeless off the streets and relieve the city’s emergency services. Experts say the program can save or extend lives, but critics wonder if the government would be better off funding treatment and sobriety programs instead.

“Established in countries such as Canada and Australia, a managed alcohol program is usually administered by a nurse and trained support staff in a facility such as a homeless shelter or a transitional or permanent home, and is one method to minimize harm for those with alcohol use disorder,” the California Health Care Foundation explains in an 2020 article describing the pilot program. 

“By prescribing limited quantities of alcohol, the model aims to prevent potentially life-threatening effects of alcohol withdrawal, such as seizures and injuries.” 

Keep reading

DEA Appears To Question Marijuana’s Medical Value Despite Rescheduling Recommendation

In the wake of the federal government’s marijuana rescheduling announcement last week that acknowledged the medical benefits of cannabis, the Drug Enforcement Administration (DEA) on Thursday released a report that appears to question the legitimacy of state medical programs.

“Marijuana remains illegal at the federal level; it has been ‘legalized’ or ‘decriminalized’ at the state level for recreational use in 24 states and the District of Columbia, and for ‘medical’ use in 38 states and the District of Columbia,” the annual National Drug Threat Assessment says, appearing to call those state-level changes and the medical value of cannabis into question by putting scare quotes around key words.

That’s despite the fact that DEA recently agreed to a Department of Health and Human Services recommendation to move cannabis to Schedule III of the Controlled Substances Act, acknowledging for the first time that cannabis has an accepted medical use in the U.S.

The comments make up only a small part of the 57-page annual report, which the agency said analyzes “illicit drug threats and trafficking trends endangering the United States.”

The top-level findings, according to a statement from DEA Administrator Anne Milgram, are that the country’s shift toward synthetic substances such as fentanyl and methamphetamine—which she blamed largely on international cartels—has caused unprecedented harm.

“The shift from plant-based drugs, like heroin and cocaine, to synthetic, chemical-based drugs, like fentanyl and methamphetamine, has resulted in the most dangerous and deadly drug crisis the United States has ever faced,” Milgram said. “At the heart of the synthetic drug crisis are the Sinaloa and Jalisco cartels and their associates, who DEA is tracking world-wide.”

“The suppliers, manufacturers, distributors, and money-launderers all play a role in the web of deliberate and calculated treachery orchestrated by these cartels,” her statement continued. “DEA will continue to use all available resources to target these networks and save American lives.”

In 2022, drug-related deaths killed 107,941 people in the United States, DEA said in its press release about the new assessment. “Fentanyl and other synthetic opioids are responsible for approximately 70% of lives lost,” it says, “while methamphetamine and other synthetic stimulants are responsible for approximately 30% of deaths.”

The agency press release doesn’t mention marijuana, though this year’s National Drug Threat Assessment itself does include some cannabis-related details.

Keep reading

Pfizer To Bypass Doctors, Pharmacies By Selling Drugs Online Directly To Consumers: Report

Pfizer is forging ahead with plans to introduce a direct-to-consumer platform for online sales of some of its medications, including Paxlovid and a migraine nasal spray.

The Defender reports that this initiative marks the latest maneuver by major pharmaceutical companies to circumvent conventional routes of distribution through primary care physicians and brick-and-mortar pharmacies. 

Pfizer is set to roll out its platform before the year’s end. 

Its website will enable patients in the U.S. to consult independent telehealth professionals for prescriptions, with an online pharmacy partner handling the fulfillment and shipping of orders, per the Financial Times.

Keep reading

Most Americans Who Have Tried Marijuana Or Psychedelics Had ‘Positive’ Experiences, Survey Finds

A majority of Americans have tried marijuana—and most say they had a positive experience—according to a new poll.

The survey from YouGov also found that one in five Americans have used psilocybin mushrooms, and an even greater majority of those respondents described the experience as positive. Most people who have tried other psychedelics like LSD and MDMA also said it was a good time.

As the federal government moves to reclassify cannabis and more states pursue psychedelics reform, the poll offers fresh insights into how people have personally used the substances and where they stand on changing drug laws.

YouGov asked respondents about four substances: marijuana, psilocybin, LSD and MDMA. By far the most commonly used was marijuana (57 percent), followed by psilocybin (20 percent), LSD (16 percent) and MDMA (11 percent).

For each substance, people who said they’ve used it reported a positive experience, most prominently for psilocybin (65). The rest were roughly equal: marijuana (57 percent), MDMA (56 percent) and LSD (55 percent).

About one and four people who’ve used the drugs described the experience as equally positive and negative. And 20 percent of people who’ve consumed marijuana, LSD or MDMA said it was a negative experience, but only eight percent said the same of psilocybin.

Keep reading

Virginia Officials Launch ‘Surveillance System’ To Track Cannabis-Related ‘Adverse Events’ Among Children

Virginia officials are instructing health care providers to start keeping track of “adverse events” involving children and teens being exposed to cannabis products.

In an April 24 letter to clinicians, State Health Commissioner Karen Shelton said her agency had received enough reports of minors getting sick from products containing CBD and THC, chemical compounds found in cannabis, that the state was establishing a “special surveillance system” to keep tabs on the issue.

“Reported symptoms for these adverse events have included vomiting, hallucinations, low blood pressure, low blood sugar, altered mental status and anxiety,” Shelton wrote, adding that “some hospitalizations have occurred” as a result of minors consuming cannabis products.

The letter specifically asks that local health departments be made aware of any cannabis-related hospitalizations in patients under 18 years old and any “clusters of adverse events” affecting multiple minors.

“After a hospitalization or cluster is reported, VDH staff will collect information about the illness(es), possible exposures, and laboratory results,” the letter says.

The Health Department provided data showing an increase in emergency room visits involving minors being exposed to cannabis, and said the new surveillance system will help bolster those tracking efforts. In 2019, there were 52 ER visits. By 2023, the number had grown to 377.

That data only covers emergency room visits and doesn’t reflect every incident reported to health officials.

“As a result of these data, the special surveillance system was established in order for VDH to receive these reports directly and better assess the impact of adverse events related to consumption of products containing THC or CBD among children in the Commonwealth,” said Health Department spokesperson Cheryle Rodriguez.

The letter also points to an online portal allowing anyone who had an adverse experience with cannabis products to submit a report to the Health Department with information about what happened, where the product was obtained and how it was labeled. The agency also noted that lab testing is available to “support patient and product testing.”

Keep reading

Church of the Eagle and the Condor Can Now Drink Ayahuasca Legally in the US

The prophecy of the Eagle and the Condor has manifested. Following a years-long legal battle, the Church of the Eagle and the Condor has successfully settled with the US Department of Justice (DOJ), the Department of Homeland Security (DHS), Customs and Border Protection (CBP), and the Drug Enforcement Administration (DEA) to legally use ayahuasca as an integral part of its religious practices, according to a press release. 

The Church of the Eagle and the Condor is officially the first non-Christian church to obtain such legal protections. This also marks the first time in history that a church has received federal authorization to import and facilitate ayahuasca without going to trial. This historic settlement has promising implications for other Indigenous-rooted and syncretic faiths hoping to work with entheogens.

“This settlement reaffirms our right to practice our spirituality as we have always known,” says Belinda P. Eriacho, board member of the Church of the Eagle and the Condor, and member of the Diné / A:shwii lineages. “It is a recognition by the US government and an important milestone in honoring and validating Indigenous belief systems.”

Keep reading

Marijuana Seizures At U.S.–Mexico Border Continue To Fall As More States Legalize, Federal Data Shows

As the state marijuana legalization movement continues to expand, seizures of cannabis at southern border declined again in 2023, according to data from U.S. Customs and Border Protection (CBP).

The latest figures show agents intercepted roughly 61,000 pounds of cannabis in the region—a 29 percent drop from the year before.

The new numbers represent an ongoing decline in illicit marijuana seizures by border agents as more U.S. state legalization laws come online. In 2022, CBP authorities seized 154,797 pounds of cannabis nationwide—about half of the 319,447 pounds that were seized the year before.

Advocates for legalization say the data from the southern border is further evidence that state-regulated markets are shrinking demand for imported Mexican marijuana.

“When it comes to cannabis, the prevailing attitude is ‘Buy American,’” NORML Deputy Director Paul Armentano said in a statement about the trend. “The rise of the regulated state-legal cannabis market has not only supplanted Americans’ demand for Mexican cannabis, but in many places it has also disrupted the unregulated domestic marketplace.”

NORML noted that the 2023 figures mark a 98 percent decline in seized cannabis at the U.S.–Mexico border since 2013, when more than 2.4 million pounds were intercepted.

The advocacy group also cited a survey from last year in which 52 percent of U.S. cannabis consumers said they primarily obtain marijuana from brick-and-mortar establishments. The poll found that just 6 percent said they primarily get cannabis from a “dealer.”

As reports in recent years have pointed out, the dynamic has shifted so significantly that, at least in some cases, U.S. marijuana is now being smuggled into Mexico, where it commands premium prices. One vehicle recently stopped by authorities as it traveled from California to Tijuana held 5,600 jars of THC-infused gummies.

NORML said similar dynamics are being observed in Canada. In 2019, the first full year of legalization in that country, just over a third (37 percent) of consumers reported buying marijuana from legal sources. By 2022, that share had nearly doubled, to 69 percent. At that point, only 4 percent of respondents said they still purchased cannabis on the unregulated market.

The CBP data tracks with other indications of declines in illegal marijuana trafficking as a growing number of state laws give American consumers legal places to buy cannabis, including a March report from the U.S. Sentencing Commission that showed federal cases continue to fall.

While that report didn’t cite the specific number of marijuana trafficking cases in 2023, it dipped again compared to the previous 2022 low of 806, according to an included chart. By comparison, there were roughly 5,000 cannabis cases in 2013.

Meanwhile, cases involving fentanyl and powder cocaine increased again last year. Drug cases overall made up 29.9 percent of the federal criminal caseload, the second-largest category after immigration-related offenses.

Keep reading

Do dying people have a ‘right to try’ magic mushrooms? 9th Circuit weighs case

Do dying patients have a “right to try” illegal drugs such as psilocybin and MDMA if they might alleviate end-of-life suffering from anxiety and depression?

That question is now before one of the nation’s highest courts, with a Seattle-based palliative care physician appealing a U.S. Drug Enforcement Administration decision barring him from prescribing psilocybin to his late-stage cancer patients.

Dr. Sunil Aggarwal says he has a right to prescribe psilocybin—the hallucinogenic compound in “magic mushrooms”—under state and federal “right to try” laws, which give terminal patients access to experimental drug therapies before they are approved by the U.S. Food and Drug Administration. More than 40 states, including Washington and California, have such laws in place, and Congress passed a federal version in 2018.

“I have patients who want to try psilocybin-assisted therapy for existential distress,” Aggarwal said in an interview with The Times. “And there are lots of studies that support that.”

The DEA has denied Aggarwal’s request, arguing that therapeutic use of psilocybin remains banned—even for terminal patients—under the Controlled Substances Act of 1970, which lists the drug as a “Schedule I” narcotic with no recognized medical use. The agency said Aggarwal could only work with the drug if he received a license to do so as a researcher, not as a regular part of his palliative care practice.

The case is one of two Aggarwal now has pending before the 9th Circuit, each pitting the DEA’s law enforcement authority against state powers to regulate medicine. In the second case, Aggarwal is asking the DEA to simply reschedule psilocybin, making it available for therapy—not just research.

Physicians and medical experts across the country are closely watching the “right to try” case, and eight states and the District of Columbia have weighed in directly in support of Aggarwal.

In February, the state coalition filed a brief that accused the DEA of reaching far beyond its law enforcement role of preventing the illegal diversion of powerful narcotics. They said the DEA’s assertion that the Controlled Substances Act trumps state right-to-try laws represented a “threat to state sovereignty.”

Keep reading

Trump Planning to Send Covert ‘Assassination Squads’ to Mexico to Take Out Cartel Leaders

Donald Trump is reportedly planning to send covert “assassination squads” into Mexico as soon as he takes office in order to take out Mexican drug cartel leaders wreaking havoc on America.

According to a report from Rolling Stone, Trump is mulling the idea if he returns to the White House next year as part of an effort to strike “fear into the hearts” of Mexico’s most notorious drug lords:

The former president has not presented specific details in public about these plans — for example, how many U.S. troops he’d be willing to send into sovereign Mexican territory. But, the three sources tell Rolling Stone, in conversations with close MAGA allies, including at least one Republican lawmaker, Trump has privately endorsed the idea of covertly deploying — with or without the Mexican government’s consent — special-ops units that would be tasked with, among other missions, assassinating the leaders and top enforcers of Mexico’s powerful and most notorious drug cartels. In some of these discussions, Trump has insisted that the U.S. military has “tougher killers than they do” and pondered why these assassination missions haven’t been done before, arguing that eliminating the heads of cartels would go a long way toward hobbling their operations and striking fear into the hearts of “the kingpins.”

…

During some of these conversations, Trump has likened these proposals to the 2019 military raid that he ordered that resulted in the death of ISIS leader Abu Bakr al-Baghdadi, insisting that the U.S. should approach drug cartel leadership in the same manner. One of the sources, who discussed the issue with Trump earlier this year, recalls the ex-president saying that the U.S. government should have a “kill list of drug lords,” as this source describes Trump’s ideas, of the most powerful and infamous cartel figures that American special forces would be assigned to kill or capture in a potential second Trump administration.

Trump has made no secret of his plans to deal with Mexico’s drug cartels should he get a second term in office. Since Joe Biden seized power in January 2021, drug cartels have expanded their operations across the United States by taking advantage of the open border, flooding the country with fentanyl and a host of other deadly substances.

Keep reading

Cannabis Can Help Treat Female Orgasmic Disorder, Study Finds As Ohio Officials Consider Adding It As Qualifying Condition

Ahead of a decision by Ohio officials on whether to add female orgasmic disorder (FOD) as a qualifying condition for the state’s medical marijuana program, a new study highlights the benefits that researchers say cannabis could offer people with the condition—including increased orgasm ease and satisfaction.

The 10-page study, published in the journal Sexual Medicine, draws on a 2022 survey of “sexually active women who used cannabis.” Among those who experienced challenges in achieving orgasm, more than 7 in 10 said cannabis use increased orgasm ease (71 percent) and frequency (72.9 percent), and two-thirds (67 percent) said it improved orgasm satisfaction.

“The results corroborate 50 years of anecdotal and learned speculation about cannabis helping women with FOD,” the paper says. “The research found that cannabis use increased orgasm frequency, eased orgasm difficulty, and improved orgasm satisfaction. At the same time, the results opened new areas of discussion.”

For example, results of the survey found that women with one or more mental health diagnoses who used cannabis before partnered sex had “a more positive orgasm response regardless of whether they have FOD,” which authors noted was “consistent with research finding that women with FOD experience high rates of mental health diagnoses, prescription drug use, or PTSD.”

Keep reading